Celltrion Sees ‘Record-High Revenue’ With Increasing Infliximab Sales
As Company Plans To Launch One Biological Product Every Year
Executive Summary
South Korea’s Celltrion has delivered a strong fourth quarter in FY21 based on the increase in infliximab sales across all markets as well as a contribution from its Regkirona COVID-19 treatment. The company expects modest top-line growth to continue by launching at least one biological product every year.
You may also be interested in...
Eurofarma Biosimilars Deal Broadens Access To Latin America For Henlius
Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.
Celltrion Launches Higher-Strength Yuflyma Adalimumab In Canada
Months after it received approval from local regulator Health Canada, Celltrion’s Yuflyma high-concentration adalimumab biosimilar is now available in the North American market, setting up a potential rivalry with Alvotech and its marketing partner JAMP Pharma.
Celltrion Celebrates Brazilian Tender Win For Infliximab
Celltrion’s Remsima infliximab biosimilar has won a Brazilian federal tender as well as several individual state bids, following earlier awards for the Korean firm’s Truxima (rituximab) and Herzuma (trastuzumab) biosimilars.